XKXiaoman Kang

Xiaoman Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoman Kang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Bohan Yao

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

    1 shared publication
  • Enshan Feng

    Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Hao Xing

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

    1 shared publication
  • Jiamin Chen

    Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

    1 shared publication
  • Lei Sun

    Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Man Li

    Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

    1 shared publication

Latest Publications

  • Open Access

    Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series

    by Yin Ren, Xiaopeng Guo, Hao Xing, Xiaoman Kang, Tingyu Liang, Yixin Shi, Bohan Yao, Wenbin Ma, Yu Wang

    Background/Objectives: Patients with high-grade glioma (HGG) have a poor prognosis despite maximal safe resection, radiotherapy, and chemotherapy, partly because of the immunosuppressive tumor microenvironment. Unfortunately, all phase III trials of anti-PD-1 therapy to date have failed to yield positive results in HGGs. Recent early-phase trials have identified promising strategies involving immune checkpoint inhibitors. Here, we share our 8-year experience with anti-PD-1 therapy in patients with HGG in a real-world setting. Methods: All patients with HGG who received PD-1 inhibitor-based therapy at our center between 2018 and 2026 were included. Medical records were reviewed longitudinally for each patient, and the latest follow-up data were collected. Patients lost to follow-up were excluded. Results: Four regimens involving anti-PD-1 treatment were identified in 22 patients with HGG (newly diagnosed = 11, recurrent = 11): (1) VEGFR-targeted therapy plus PD-1 inhibition (9 recurrent HGGs), (2) the “2-THE-TOP” regimen (tumor-treating fields plus temozolomide and PD-1 inhibitor therapy) (5 newly diagnosed HGGs), (3) anti-PD-1 monotherapy (2 recurrent and 2 newly diagnosed HGGs), and (4) neoadjuvant plus adjuvant anti-PD-1 therapy (4 newly diagnosed HGGs). Median overall survival for these four regimens was 32.7, 20.3, 28.6, and 31.8 months, respectively. No grade 3–4 treatment-related adverse events were recorded. Conclusions: Our preliminary observations suggest that PD-1 blockade may remain a viable option for patients with HGG when combined with specific therapies, administered with careful timing, and applied in selected patients.

  • Open Access

    PDL1 Gene Gain Predicts an Unfavorable Prognosis in HIV-Positive Primary Central Nervous System Lymphoma

    by Jiamin Chen, Xiaoman Kang, Xinghuan Ding, Yuyang Dai, Lei Sun, Man Li, Ting Liu, Enshan Feng, Xingang Zhou

    Primary central nervous system lymphoma (PCNSL) refers to non-Hodgkin lymphoma (NHL) originating in the brain, eyes, spinal cord, and cerebrospinal fluid without the presence of lymphoma outside of the central nervous system